المؤلفون: Lillegraven S; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway., Paulshus Sundlisæter N; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway., Aga AB; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway., Sexton J; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway., Olsen IC; Clinical Trial Unit, Oslo University Hospital, Oslo, Norway., Fremstad H; Department of Rheumatology, Ålesund Hospital, Helse Møre og Romsdal HF, Ålesund, Norway., Spada C; Revmatismesykehuset AS, Lillehammer, Norway., Madland TM; Department of Rheumatology, Haukeland University Hospital, Bergen, Norway., Høili CA; Department of Rheumatology, Hospital Østfold HF, Moss, Norway., Bakland G; Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway., Lexberg Å; Department of Rheumatology, Drammen Hospital, Vestre Viken HF, Drammen, Norway., Hansen IJW; Department of Rheumatology, Sørlandet Hospital HF, Kristiansand, Norway., Hansen IM; Department of Rheumatology, Helgelandssykehuset Mo i Rana, Mo i Rana, Norway., Haukeland H; Department of Rheumatology, Martina Hansens Hospital, Bærum, Norway., Ljoså MA; Department of Rheumatology, Ålesund Hospital, Helse Møre og Romsdal HF, Ålesund, Norway., Moholt E; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway., Uhlig T; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.; Faculty of Medicine, University of Oslo, Oslo, Norway., Solomon DH; Division of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts., van der Heijde D; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.; Department of Rheumatology, Leiden University Medical Centre, Leiden, the Netherlands., Kvien TK; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.; Faculty of Medicine, University of Oslo, Oslo, Norway., Haavardsholm EA; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.; Faculty of Medicine, University of Oslo, Oslo, Norway.

المصدر: JAMA [JAMA] 2021 May 04; Vol. 325 (17), pp. 1755-1764.

نوع المنشور: Equivalence Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Medical Association Country of Publication: United States NLM ID: 7501160 Publication Model: Print Cited Medium: Internet ISSN: 1538-3598 (Electronic) Linking ISSN: 00987484 NLM ISO Abbreviation: JAMA Subsets: MEDLINE

مواضيع طبية MeSH: Symptom Flare Up*, Antirheumatic Agents/*administration & dosage , Arthritis, Rheumatoid/*drug therapy , Methotrexate/*administration & dosage, Adult ; Aged ; Antirheumatic Agents/adverse effects ; Arthritis, Rheumatoid/diagnostic imaging ; Arthritis, Rheumatoid/pathology ; Dose-Response Relationship, Drug ; Drug Therapy, Combination ; Female ; Humans ; Hydroxychloroquine/administration & dosage ; Leflunomide/administration & dosage ; Male ; Methotrexate/adverse effects ; Middle Aged ; Radiography ; Sulfasalazine/administration & dosage ; Ultrasonography

المؤلفون: Emery P; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK., Horton S; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.; Central Lancashire Moving Well Service, Lancashire and South Cumbria NHS Foundation Trust, Preston, UK., Dumitru RB; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK., Naraghi K; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK., van der Heijde D; Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands., Wakefield RJ; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK., Hensor EMA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK., Buch MH; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK maya.buch@manchester.ac.uk.; Centre for Musculoskeletal Research, School of Biological Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Manchester, UK.; NIHR Manchester Biomedical Research Centre, Manchester Academic Health Science Centre, Manchester University Foundation Trust, Manchester, UK.

المصدر: Annals of the rheumatic diseases [Ann Rheum Dis] 2020 Apr; Vol. 79 (4), pp. 464-471. Date of Electronic Publication: 2020 Jan 29.

نوع المنشور: Clinical Trial, Phase IV; Journal Article; Pragmatic Clinical Trial; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: BMJ Country of Publication: England NLM ID: 0372355 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-2060 (Electronic) Linking ISSN: 00034967 NLM ISO Abbreviation: Ann Rheum Dis Subsets: MEDLINE

مواضيع طبية MeSH: Antirheumatic Agents/*therapeutic use , Arthritis, Rheumatoid/*drug therapy , Etanercept/*therapeutic use , Methotrexate/*therapeutic use , Tumor Necrosis Factor Inhibitors/*therapeutic use, Adult ; Arthritis, Rheumatoid/physiopathology ; Drug Therapy, Combination ; Early Medical Intervention ; Female ; Humans ; Male ; Middle Aged ; Time Factors ; Treatment Outcome

المؤلفون: Genovese MC; Stanford University Medical Center, Palo Alto, California, USA., van der Heijde D; Leiden University Medical Centre, Leiden, The Netherlands., Lin Y; Sanofi Genzyme, Bridgewater, New Jersey, USA., St John G; Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA., Wang S; Sanofi Genzyme, Bridgewater, New Jersey, USA., van Hoogstraten H; Sanofi Genzyme, Bridgewater, New Jersey, USA., Gómez-Reino JJ; Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain., Kivitz A; Altoona Center for Clinical Research, Duncansville, Pennsylvania, USA., Maldonado-Cocco JA; School of Medicine, University of Buenos Aires, Buenos Aires, Argentina., Seriolo B; Department of Internal Medicine, University of Genova, Genova, Italy., Stanislav M; Research Rheumatology Institute n. a. V.A. Nasonova, Moscow, Russia., Burmester GR; Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany.

المصدر: RMD open [RMD Open] 2019 Aug 01; Vol. 5 (2), pp. e000887. Date of Electronic Publication: 2019 Aug 01 (Print Publication: 2019).

نوع المنشور: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: BMJ Publishing Group Country of Publication: England NLM ID: 101662038 Publication Model: eCollection Cited Medium: Print ISSN: 2056-5933 (Print) Linking ISSN: 20565933 NLM ISO Abbreviation: RMD Open

مواضيع طبية MeSH: Antibodies, Monoclonal, Humanized/*therapeutic use , Antirheumatic Agents/*therapeutic use , Arthritis, Rheumatoid/*drug therapy , Methotrexate/*therapeutic use, Adult ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/adverse effects ; Antirheumatic Agents/administration & dosage ; Antirheumatic Agents/adverse effects ; Arthritis, Rheumatoid/diagnostic imaging ; Arthritis, Rheumatoid/physiopathology ; C-Reactive Protein/drug effects ; Disease Progression ; Drug Therapy, Combination ; Exercise ; Female ; Humans ; Injections, Subcutaneous/methods ; Male ; Methotrexate/administration & dosage ; Methotrexate/adverse effects ; Middle Aged ; Neutrophils/drug effects ; Patient Safety ; Placebos/administration & dosage ; Radiography/statistics & numerical data ; Radiography/trends ; Receptors, Interleukin-6/antagonists & inhibitors ; Treatment Outcome

المؤلفون: van der Heijde D; Leiden University Medical Center, Leiden, The Netherlands., Strand V; Biopharmaceutical Consultant, Portola Valley, California., Tanaka Y; University of Occupational and Environmental Health, Kitakyushu, Japan., Keystone E; Mount Sinai Hospital, Toronto, Ontario, Canada., Kremer J; Albany Medical College, Albany, New York., Zerbini CAF; Centro Paulista de Investigação Clinica, Sao Paulo, Brazil., Cardiel MH; Centro de Investigacion Clinica de Morelia, Morelia, Mexico., Cohen S; Metroplex Clinical Research Center, Dallas, Texas., Nash P; Nambour General Hospital, Nambour, Queensland, Australia, and University of Queensland, Brisbane, Queensland, Australia., Song YW; Seoul National University Hospital, Seoul, Republic of Korea., Tegzová D; Institute of Rheumatology, Prague, Czech Republic., Gruben D; Pfizer, Inc., Groton, Connecticut., Wallenstein G; Pfizer, Inc., Groton, Connecticut., Connell CA; Pfizer, Inc., Groton, Connecticut., Fleischmann R; Metroplex Clinical Research Center, Dallas, Texas.

مؤلفون مشاركون: ORAL Scan Investigators

المصدر: Arthritis & rheumatology (Hoboken, N.J.) [Arthritis Rheumatol] 2019 Jun; Vol. 71 (6), pp. 878-891. Date of Electronic Publication: 2019 Apr 24.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 101623795 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2326-5205 (Electronic) Linking ISSN: 23265191 NLM ISO Abbreviation: Arthritis Rheumatol Subsets: MEDLINE

مواضيع طبية MeSH: Antirheumatic Agents/*therapeutic use , Arthritis, Rheumatoid/*drug therapy , Janus Kinase Inhibitors/*therapeutic use , Methotrexate/*therapeutic use , Piperidines/*therapeutic use , Pyrimidines/*therapeutic use , Pyrroles/*therapeutic use, Adult ; Arthritis, Rheumatoid/diagnostic imaging ; Arthritis, Rheumatoid/physiopathology ; Drug Therapy, Combination ; Female ; Humans ; Male ; Middle Aged ; Treatment Outcome

المؤلفون: Ishiguro N; Department of Orthopaedics, Nagoya University Graduate School of Medicine, Nagoya, Aichi., Tanaka Y; First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu., Yamanaka H; Institute of Rheumatology, Tokyo Women's Medical University, Tokyo., Yoneda T; Department of Biochemistry, Osaka University Graduate School of Dentistry, Osaka., Ohira T; Daiichi-Sankyo Co., Ltd, Tokyo, Japan., Okubo N; Daiichi-Sankyo Co., Ltd, Tokyo, Japan., Genant HK; Departments of Radiology, Medicine and Orthopaedic Surgery, University of California, San Francisco, CA, USA., van der Heijde D; Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands., Takeuchi T; Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.

المصدر: Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2019 Jun 01; Vol. 58 (6), pp. 997-1005.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 100883501 Publication Model: Print Cited Medium: Internet ISSN: 1462-0332 (Electronic) Linking ISSN: 14620324 NLM ISO Abbreviation: Rheumatology (Oxford) Subsets: MEDLINE

مواضيع طبية MeSH: Arthritis, Rheumatoid/*drug therapy , Bone Density/*drug effects , Bone Density Conservation Agents/*therapeutic use , Bone Resorption/*drug therapy , Denosumab/*therapeutic use , Methotrexate/*therapeutic use, Adult ; Aged ; Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/blood ; Arthritis, Rheumatoid/complications ; Bone Density Conservation Agents/administration & dosage ; Bone Resorption/blood ; Bone Resorption/etiology ; Denosumab/administration & dosage ; Disease Progression ; Double-Blind Method ; Female ; Humans ; Japan ; Male ; Middle Aged ; Prognosis ; Rheumatoid Factor/blood ; Treatment Outcome

المؤلفون: Stamm TA; Section for Outcomes Research, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.; Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria., Machold KP; Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria., Aletaha D; Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria., Alasti F; Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria., Lipsky P; RILITE Research Institute, 250 W Main Street, Charlottesville, Virginia, 22902, USA., Pisetsky D; Medical Research Service Durham VA Medical Center, and Duke University Medical Center, 151G Durham VA Medical Center, 508 Fulton Street, Durham, North Carolina, 27705, USA., Landewe R; Department of Medicine, Division of Rheumatology, Academic Medical Center Amsterdam, Amsterdam, The Netherlands., van der Heijde D; Department of Rheumatology, Leiden University Medical Centre, Albinusdreef 2, PO Box 9600, 2300 RC, Leiden, The Netherlands., Sepriano A; Department of Rheumatology, Leiden University Medical Centre, Albinusdreef 2, PO Box 9600, 2300 RC, Leiden, The Netherlands., Aringer M; Division of Rheumatology, Department of Medicine III, University Medical Center and Faculty of Medicine Carl Gustav Carus at the TU Dresden, Fetscherstrasse 74, 01309, Dresden, Germany., Boumpas D; Rheumatology Medical School University of Crete, Heraklion and Joint Rheumatology Program, National and Kapodestrian University of Athens, Athens, Greece., Burmester G; Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany., Cutolo M; Research Laboratory and Division of Rheumatology, Department of Internal Medicine, University of Genova, Viale Benedetto XV, 6, 16132, Genoa, Italy., Ebner W; Department of Internal Medicine, Centre for Rheumatic Diseases, Hietzing Hospital, Wolkersbergenstraße 1, 1130, Vienna, Austria., Graninger W; Department of Rheumatology, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Styria, Austria., Huizinga T; Department of Rheumatology, Leiden University Medical Centre, Albinusdreef 2, PO Box 9600, 2300 RC, Leiden, The Netherlands., Schett G; Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Ulmenweg 18, 91054, Erlangen, Germany., Schulze-Koops H; Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, Ludwig Maximilians University of Munich, Pettenkoferstraße 8a, 80336, Munich, Germany., Tak PP; Amsterdam Rheumatology and Immunology Center, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands.; Department of Medicine, Cambridge University, Cambridge, UK.; Department of Rheumatology, Ghent University, Ghent, Belgium.; GlaxoSmithKline Research & Development, Stevenage, UK., Martin-Mola E; Hospital Universitario La Paz, Paseo de la Castellana 261, 28046, Madrid, Spain., Breedveld F; Leiden University Medical Center, Albinusdreef 2, PO Box 9600, 2300 RC, Leiden, The Netherlands., Smolen J; Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. josef.smolen@meduniwien.ac.at.; Department of Internal Medicine, Centre for Rheumatic Diseases, Hietzing Hospital, Wolkersbergenstraße 1, 1130, Vienna, Austria. josef.smolen@meduniwien.ac.at.

المصدر: Arthritis research & therapy [Arthritis Res Ther] 2018 Aug 09; Vol. 20 (1), pp. 174. Date of Electronic Publication: 2018 Aug 09.

نوع المنشور: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101154438 Publication Model: Electronic Cited Medium: Internet ISSN: 1478-6362 (Electronic) Linking ISSN: 14786354 NLM ISO Abbreviation: Arthritis Res Ther Subsets: MEDLINE

مواضيع طبية MeSH: Antirheumatic Agents/*administration & dosage , Arthritis, Rheumatoid/*drug therapy , Infliximab/*administration & dosage , Methotrexate/*administration & dosage, Adult ; Aged ; Double-Blind Method ; Drug Therapy, Combination ; Female ; Humans ; Male ; Middle Aged ; Remission Induction ; Treatment Outcome

المؤلفون: Genovese MC; Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA., van Adelsberg J; Regeneron Pharmaceuticals, Inc., Tarrytown, NJ., Fan C; Sanofi Genzyme, Bridgewater, NJ, USA., Graham NMH; Regeneron Pharmaceuticals, Inc., Tarrytown, NJ., van Hoogstraten H; Sanofi Genzyme, Bridgewater, NJ, USA., Parrino J; Regeneron Pharmaceuticals, Inc., Tarrytown, NJ., Mangan EK; Regeneron Pharmaceuticals, Inc., Tarrytown, NJ., Spindler A; Centro Medico Privado de Reumatologia, Tucumán, Argentina., Huizinga TWJ; Department of Rheumatology, Leiden University Medical Centre, Leiden, the Netherlands., van der Heijde D; Department of Rheumatology, Leiden University Medical Centre, Leiden, the Netherlands.

مؤلفون مشاركون: EXTEND study investigators

المصدر: Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2018 Aug 01; Vol. 57 (8), pp. 1423-1431.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 100883501 Publication Model: Print Cited Medium: Internet ISSN: 1462-0332 (Electronic) Linking ISSN: 14620324 NLM ISO Abbreviation: Rheumatology (Oxford) Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal, Humanized/*administration & dosage , Arthritis, Rheumatoid/*drug therapy , Methotrexate/*administration & dosage , Radiography/*methods, Antirheumatic Agents/administration & dosage ; Arthritis, Rheumatoid/diagnosis ; Disease Progression ; Dose-Response Relationship, Drug ; Double-Blind Method ; Female ; Follow-Up Studies ; Humans ; Injections, Subcutaneous ; Male ; Middle Aged ; Severity of Illness Index ; Time Factors ; Treatment Outcome

المؤلفون: Charles-Schoeman C; From the University of California at Los Angeles (UCLA), Los Angeles, California, USA; Leiden University Medical Center, Leiden, the Netherlands; Charité-University Medicine Berlin Free University and Humboldt University of Berlin, Berlin, Germany; Department of Medicine, University of Queensland, Queensland, Australia; Centro Paulista de Investigação Clinica, São Paulo, Brazil; Pfizer Inc., Groton, Connecticut; Pfizer Inc., Collegeville, Pennsylvania; Pfizer Inc., New York, New York; Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, Texas, USA.; C. Charles-Schoeman has received research grants and consulting fees from Pfizer Inc. D. van der Heijde has received consulting fees from Pfizer Inc., and is the Director of Imaging Rheumatology BV. G.R. Burmester has received consulting fees from, and is on the speakers' bureau for, Pfizer Inc. P. Nash has received research grants and honoraria for advice and lectures from AbbVie, Lilly, Novartis, Pfizer Inc., Sanofi, Roche, and UCB. C.A. Zerbini has received research grants from, and is on the speakers' bureau for, Pfizer Inc. R. Fleischmann has received research grants and consulting fees from Pfizer Inc.; C. Charles-Schoeman, MD, MS, Associate Professor of Medicine, UCLA; D. van der Heijde, MD, PhD, Professor of Rheumatology, Leiden University Medical Center; G.R. Burmester, MD, Professor of Medicine and Director, Department of Rheumatology and Clinical Immunology, Charité-University Medicine Berlin Free University and Humboldt University of Berlin; P. Nash, MBBS, FRACP, Director, Rheumatology Research Unit, Nambour Hospital, and Associate Professor, Department of Medicine, University of Queensland; C.A. Zerbini, MD, Director, Centro Paulista de Investigação Clinica; C.A. Connell, PhD, Senior Director of Clinical Research, Pfizer Inc., Groton; H. Fan, MS, Statistician/Director, Pfizer Inc., Collegeville; K. Kwok, MS, Director of Biostatistics, Pfizer Inc., New York; E. Bananis, PhD, Medical Director, Pfizer Inc., New York; R. Fleischmann, MD, Co-medical Director, Metroplex Clinical Research Center, and Clinical Professor, Department of Internal Medicine, University of Texas Southwestern Medical Center., van der Heijde D; From the University of California at Los Angeles (UCLA), Los Angeles, California, USA; Leiden University Medical Center, Leiden, the Netherlands; Charité-University Medicine Berlin Free University and Humboldt University of Berlin, Berlin, Germany; Department of Medicine, University of Queensland, Queensland, Australia; Centro Paulista de Investigação Clinica, São Paulo, Brazil; Pfizer Inc., Groton, Connecticut; Pfizer Inc., Collegeville, Pennsylvania; Pfizer Inc., New York, New York; Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, Texas, USA.; C. Charles-Schoeman has received research grants and consulting fees from Pfizer Inc. D. van der Heijde has received consulting fees from Pfizer Inc., and is the Director of Imaging Rheumatology BV. G.R. Burmester has received consulting fees from, and is on the speakers' bureau for, Pfizer Inc. P. Nash has received research grants and honoraria for advice and lectures from AbbVie, Lilly, Novartis, Pfizer Inc., Sanofi, Roche, and UCB. C.A. Zerbini has received research grants from, and is on the speakers' bureau for, Pfizer Inc. R. Fleischmann has received research grants and consulting fees from Pfizer Inc.; C. Charles-Schoeman, MD, MS, Associate Professor of Medicine, UCLA; D. van der Heijde, MD, PhD, Professor of Rheumatology, Leiden University Medical Center; G.R. Burmester, MD, Professor of Medicine and Director, Department of Rheumatology and Clinical Immunology, Charité-University Medicine Berlin Free University and Humboldt University of Berlin; P. Nash, MBBS, FRACP, Director, Rheumatology Research Unit, Nambour Hospital, and Associate Professor, Department of Medicine, University of Queensland; C.A. Zerbini, MD, Director, Centro Paulista de Investigação Clinica; C.A. Connell, PhD, Senior Director of Clinical Research, Pfizer Inc., Groton; H. Fan, MS, Statistician/Director, Pfizer Inc., Collegeville; K. Kwok, MS, Director of Biostatistics, Pfizer Inc., New York; E. Bananis, PhD, Medical Director, Pfizer Inc., New York; R. Fleischmann, MD, Co-medical Director, Metroplex Clinical Research Center, and Clinical Professor, Department of Internal Medicine, University of Texas Southwestern Medical Center., Burmester GR; From the University of California at Los Angeles (UCLA), Los Angeles, California, USA; Leiden University Medical Center, Leiden, the Netherlands; Charité-University Medicine Berlin Free University and Humboldt University of Berlin, Berlin, Germany; Department of Medicine, University of Queensland, Queensland, Australia; Centro Paulista de Investigação Clinica, São Paulo, Brazil; Pfizer Inc., Groton, Connecticut; Pfizer Inc., Collegeville, Pennsylvania; Pfizer Inc., New York, New York; Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, Texas, USA.; C. Charles-Schoeman has received research grants and consulting fees from Pfizer Inc. D. van der Heijde has received consulting fees from Pfizer Inc., and is the Director of Imaging Rheumatology BV. G.R. Burmester has received consulting fees from, and is on the speakers' bureau for, Pfizer Inc. P. Nash has received research grants and honoraria for advice and lectures from AbbVie, Lilly, Novartis, Pfizer Inc., Sanofi, Roche, and UCB. C.A. Zerbini has received research grants from, and is on the speakers' bureau for, Pfizer Inc. R. Fleischmann has received research grants and consulting fees from Pfizer Inc.; C. Charles-Schoeman, MD, MS, Associate Professor of Medicine, UCLA; D. van der Heijde, MD, PhD, Professor of Rheumatology, Leiden University Medical Center; G.R. Burmester, MD, Professor of Medicine and Director, Department of Rheumatology and Clinical Immunology, Charité-University Medicine Berlin Free University and Humboldt University of Berlin; P. Nash, MBBS, FRACP, Director, Rheumatology Research Unit, Nambour Hospital, and Associate Professor, Department of Medicine, University of Queensland; C.A. Zerbini, MD, Director, Centro Paulista de Investigação Clinica; C.A. Connell, PhD, Senior Director of Clinical Research, Pfizer Inc., Groton; H. Fan, MS, Statistician/Director, Pfizer Inc., Collegeville; K. Kwok, MS, Director of Biostatistics, Pfizer Inc., New York; E. Bananis, PhD, Medical Director, Pfizer Inc., New York; R. Fleischmann, MD, Co-medical Director, Metroplex Clinical Research Center, and Clinical Professor, Department of Internal Medicine, University of Texas Southwestern Medical Center., Nash P; From the University of California at Los Angeles (UCLA), Los Angeles, California, USA; Leiden University Medical Center, Leiden, the Netherlands; Charité-University Medicine Berlin Free University and Humboldt University of Berlin, Berlin, Germany; Department of Medicine, University of Queensland, Queensland, Australia; Centro Paulista de Investigação Clinica, São Paulo, Brazil; Pfizer Inc., Groton, Connecticut; Pfizer Inc., Collegeville, Pennsylvania; Pfizer Inc., New York, New York; Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, Texas, USA.; C. Charles-Schoeman has received research grants and consulting fees from Pfizer Inc. D. van der Heijde has received consulting fees from Pfizer Inc., and is the Director of Imaging Rheumatology BV. G.R. Burmester has received consulting fees from, and is on the speakers' bureau for, Pfizer Inc. P. Nash has received research grants and honoraria for advice and lectures from AbbVie, Lilly, Novartis, Pfizer Inc., Sanofi, Roche, and UCB. C.A. Zerbini has received research grants from, and is on the speakers' bureau for, Pfizer Inc. R. Fleischmann has received research grants and consulting fees from Pfizer Inc.; C. Charles-Schoeman, MD, MS, Associate Professor of Medicine, UCLA; D. van der Heijde, MD, PhD, Professor of Rheumatology, Leiden University Medical Center; G.R. Burmester, MD, Professor of Medicine and Director, Department of Rheumatology and Clinical Immunology, Charité-University Medicine Berlin Free University and Humboldt University of Berlin; P. Nash, MBBS, FRACP, Director, Rheumatology Research Unit, Nambour Hospital, and Associate Professor, Department of Medicine, University of Queensland; C.A. Zerbini, MD, Director, Centro Paulista de Investigação Clinica; C.A. Connell, PhD, Senior Director of Clinical Research, Pfizer Inc., Groton; H. Fan, MS, Statistician/Director, Pfizer Inc., Collegeville; K. Kwok, MS, Director of Biostatistics, Pfizer Inc., New York; E. Bananis, PhD, Medical Director, Pfizer Inc., New York; R. Fleischmann, MD, Co-medical Director, Metroplex Clinical Research Center, and Clinical Professor, Department of Internal Medicine, University of Texas Southwestern Medical Center., Zerbini CAF; From the University of California at Los Angeles (UCLA), Los Angeles, California, USA; Leiden University Medical Center, Leiden, the Netherlands; Charité-University Medicine Berlin Free University and Humboldt University of Berlin, Berlin, Germany; Department of Medicine, University of Queensland, Queensland, Australia; Centro Paulista de Investigação Clinica, São Paulo, Brazil; Pfizer Inc., Groton, Connecticut; Pfizer Inc., Collegeville, Pennsylvania; Pfizer Inc., New York, New York; Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, Texas, USA.; C. Charles-Schoeman has received research grants and consulting fees from Pfizer Inc. D. van der Heijde has received consulting fees from Pfizer Inc., and is the Director of Imaging Rheumatology BV. G.R. Burmester has received consulting fees from, and is on the speakers' bureau for, Pfizer Inc. P. Nash has received research grants and honoraria for advice and lectures from AbbVie, Lilly, Novartis, Pfizer Inc., Sanofi, Roche, and UCB. C.A. Zerbini has received research grants from, and is on the speakers' bureau for, Pfizer Inc. R. Fleischmann has received research grants and consulting fees from Pfizer Inc.; C. Charles-Schoeman, MD, MS, Associate Professor of Medicine, UCLA; D. van der Heijde, MD, PhD, Professor of Rheumatology, Leiden University Medical Center; G.R. Burmester, MD, Professor of Medicine and Director, Department of Rheumatology and Clinical Immunology, Charité-University Medicine Berlin Free University and Humboldt University of Berlin; P. Nash, MBBS, FRACP, Director, Rheumatology Research Unit, Nambour Hospital, and Associate Professor, Department of Medicine, University of Queensland; C.A. Zerbini, MD, Director, Centro Paulista de Investigação Clinica; C.A. Connell, PhD, Senior Director of Clinical Research, Pfizer Inc., Groton; H. Fan, MS, Statistician/Director, Pfizer Inc., Collegeville; K. Kwok, MS, Director of Biostatistics, Pfizer Inc., New York; E. Bananis, PhD, Medical Director, Pfizer Inc., New York; R. Fleischmann, MD, Co-medical Director, Metroplex Clinical Research Center, and Clinical Professor, Department of Internal Medicine, University of Texas Southwestern Medical Center., Connell CA; From the University of California at Los Angeles (UCLA), Los Angeles, California, USA; Leiden University Medical Center, Leiden, the Netherlands; Charité-University Medicine Berlin Free University and Humboldt University of Berlin, Berlin, Germany; Department of Medicine, University of Queensland, Queensland, Australia; Centro Paulista de Investigação Clinica, São Paulo, Brazil; Pfizer Inc., Groton, Connecticut; Pfizer Inc., Collegeville, Pennsylvania; Pfizer Inc., New York, New York; Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, Texas, USA.; C. Charles-Schoeman has received research grants and consulting fees from Pfizer Inc. D. van der Heijde has received consulting fees from Pfizer Inc., and is the Director of Imaging Rheumatology BV. G.R. Burmester has received consulting fees from, and is on the speakers' bureau for, Pfizer Inc. P. Nash has received research grants and honoraria for advice and lectures from AbbVie, Lilly, Novartis, Pfizer Inc., Sanofi, Roche, and UCB. C.A. Zerbini has received research grants from, and is on the speakers' bureau for, Pfizer Inc. R. Fleischmann has received research grants and consulting fees from Pfizer Inc.; C. Charles-Schoeman, MD, MS, Associate Professor of Medicine, UCLA; D. van der Heijde, MD, PhD, Professor of Rheumatology, Leiden University Medical Center; G.R. Burmester, MD, Professor of Medicine and Director, Department of Rheumatology and Clinical Immunology, Charité-University Medicine Berlin Free University and Humboldt University of Berlin; P. Nash, MBBS, FRACP, Director, Rheumatology Research Unit, Nambour Hospital, and Associate Professor, Department of Medicine, University of Queensland; C.A. Zerbini, MD, Director, Centro Paulista de Investigação Clinica; C.A. Connell, PhD, Senior Director of Clinical Research, Pfizer Inc., Groton; H. Fan, MS, Statistician/Director, Pfizer Inc., Collegeville; K. Kwok, MS, Director of Biostatistics, Pfizer Inc., New York; E. Bananis, PhD, Medical Director, Pfizer Inc., New York; R. Fleischmann, MD, Co-medical Director, Metroplex Clinical Research Center, and Clinical Professor, Department of Internal Medicine, University of Texas Southwestern Medical Center., Fan H; From the University of California at Los Angeles (UCLA), Los Angeles, California, USA; Leiden University Medical Center, Leiden, the Netherlands; Charité-University Medicine Berlin Free University and Humboldt University of Berlin, Berlin, Germany; Department of Medicine, University of Queensland, Queensland, Australia; Centro Paulista de Investigação Clinica, São Paulo, Brazil; Pfizer Inc., Groton, Connecticut; Pfizer Inc., Collegeville, Pennsylvania; Pfizer Inc., New York, New York; Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, Texas, USA.; C. Charles-Schoeman has received research grants and consulting fees from Pfizer Inc. D. van der Heijde has received consulting fees from Pfizer Inc., and is the Director of Imaging Rheumatology BV. G.R. Burmester has received consulting fees from, and is on the speakers' bureau for, Pfizer Inc. P. Nash has received research grants and honoraria for advice and lectures from AbbVie, Lilly, Novartis, Pfizer Inc., Sanofi, Roche, and UCB. C.A. Zerbini has received research grants from, and is on the speakers' bureau for, Pfizer Inc. R. Fleischmann has received research grants and consulting fees from Pfizer Inc.; C. Charles-Schoeman, MD, MS, Associate Professor of Medicine, UCLA; D. van der Heijde, MD, PhD, Professor of Rheumatology, Leiden University Medical Center; G.R. Burmester, MD, Professor of Medicine and Director, Department of Rheumatology and Clinical Immunology, Charité-University Medicine Berlin Free University and Humboldt University of Berlin; P. Nash, MBBS, FRACP, Director, Rheumatology Research Unit, Nambour Hospital, and Associate Professor, Department of Medicine, University of Queensland; C.A. Zerbini, MD, Director, Centro Paulista de Investigação Clinica; C.A. Connell, PhD, Senior Director of Clinical Research, Pfizer Inc., Groton; H. Fan, MS, Statistician/Director, Pfizer Inc., Collegeville; K. Kwok, MS, Director of Biostatistics, Pfizer Inc., New York; E. Bananis, PhD, Medical Director, Pfizer Inc., New York; R. Fleischmann, MD, Co-medical Director, Metroplex Clinical Research Center, and Clinical Professor, Department of Internal Medicine, University of Texas Southwestern Medical Center., Kwok K; From the University of California at Los Angeles (UCLA), Los Angeles, California, USA; Leiden University Medical Center, Leiden, the Netherlands; Charité-University Medicine Berlin Free University and Humboldt University of Berlin, Berlin, Germany; Department of Medicine, University of Queensland, Queensland, Australia; Centro Paulista de Investigação Clinica, São Paulo, Brazil; Pfizer Inc., Groton, Connecticut; Pfizer Inc., Collegeville, Pennsylvania; Pfizer Inc., New York, New York; Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, Texas, USA.; C. Charles-Schoeman has received research grants and consulting fees from Pfizer Inc. D. van der Heijde has received consulting fees from Pfizer Inc., and is the Director of Imaging Rheumatology BV. G.R. Burmester has received consulting fees from, and is on the speakers' bureau for, Pfizer Inc. P. Nash has received research grants and honoraria for advice and lectures from AbbVie, Lilly, Novartis, Pfizer Inc., Sanofi, Roche, and UCB. C.A. Zerbini has received research grants from, and is on the speakers' bureau for, Pfizer Inc. R. Fleischmann has received research grants and consulting fees from Pfizer Inc.; C. Charles-Schoeman, MD, MS, Associate Professor of Medicine, UCLA; D. van der Heijde, MD, PhD, Professor of Rheumatology, Leiden University Medical Center; G.R. Burmester, MD, Professor of Medicine and Director, Department of Rheumatology and Clinical Immunology, Charité-University Medicine Berlin Free University and Humboldt University of Berlin; P. Nash, MBBS, FRACP, Director, Rheumatology Research Unit, Nambour Hospital, and Associate Professor, Department of Medicine, University of Queensland; C.A. Zerbini, MD, Director, Centro Paulista de Investigação Clinica; C.A. Connell, PhD, Senior Director of Clinical Research, Pfizer Inc., Groton; H. Fan, MS, Statistician/Director, Pfizer Inc., Collegeville; K. Kwok, MS, Director of Biostatistics, Pfizer Inc., New York; E. Bananis, PhD, Medical Director, Pfizer Inc., New York; R. Fleischmann, MD, Co-medical Director, Metroplex Clinical Research Center, and Clinical Professor, Department of Internal Medicine, University of Texas Southwestern Medical Center., Bananis E; From the University of California at Los Angeles (UCLA), Los Angeles, California, USA; Leiden University Medical Center, Leiden, the Netherlands; Charité-University Medicine Berlin Free University and Humboldt University of Berlin, Berlin, Germany; Department of Medicine, University of Queensland, Queensland, Australia; Centro Paulista de Investigação Clinica, São Paulo, Brazil; Pfizer Inc., Groton, Connecticut; Pfizer Inc., Collegeville, Pennsylvania; Pfizer Inc., New York, New York; Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, Texas, USA. stratis.bananis@pfizer.com.; C. Charles-Schoeman has received research grants and consulting fees from Pfizer Inc. D. van der Heijde has received consulting fees from Pfizer Inc., and is the Director of Imaging Rheumatology BV. G.R. Burmester has received consulting fees from, and is on the speakers' bureau for, Pfizer Inc. P. Nash has received research grants and honoraria for advice and lectures from AbbVie, Lilly, Novartis, Pfizer Inc., Sanofi, Roche, and UCB. C.A. Zerbini has received research grants from, and is on the speakers' bureau for, Pfizer Inc. R. Fleischmann has received research grants and consulting fees from Pfizer Inc. stratis.bananis@pfizer.com.; C. Charles-Schoeman, MD, MS, Associate Professor of Medicine, UCLA; D. van der Heijde, MD, PhD, Professor of Rheumatology, Leiden University Medical Center; G.R. Burmester, MD, Professor of Medicine and Director, Department of Rheumatology and Clinical Immunology, Charité-University Medicine Berlin Free University and Humboldt University of Berlin; P. Nash, MBBS, FRACP, Director, Rheumatology Research Unit, Nambour Hospital, and Associate Professor, Department of Medicine, University of Queensland; C.A. Zerbini, MD, Director, Centro Paulista de Investigação Clinica; C.A. Connell, PhD, Senior Director of Clinical Research, Pfizer Inc., Groton; H. Fan, MS, Statistician/Director, Pfizer Inc., Collegeville; K. Kwok, MS, Director of Biostatistics, Pfizer Inc., New York; E. Bananis, PhD, Medical Director, Pfizer Inc., New York; R. Fleischmann, MD, Co-medical Director, Metroplex Clinical Research Center, and Clinical Professor, Department of Internal Medicine, University of Texas Southwestern Medical Center. stratis.bananis@pfizer.com., Fleischmann R; From the University of California at Los Angeles (UCLA), Los Angeles, California, USA; Leiden University Medical Center, Leiden, the Netherlands; Charité-University Medicine Berlin Free University and Humboldt University of Berlin, Berlin, Germany; Department of Medicine, University of Queensland, Queensland, Australia; Centro Paulista de Investigação Clinica, São Paulo, Brazil; Pfizer Inc., Groton, Connecticut; Pfizer Inc., Collegeville, Pennsylvania; Pfizer Inc., New York, New York; Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, Texas, USA.; C. Charles-Schoeman has received research grants and consulting fees from Pfizer Inc. D. van der Heijde has received consulting fees from Pfizer Inc., and is the Director of Imaging Rheumatology BV. G.R. Burmester has received consulting fees from, and is on the speakers' bureau for, Pfizer Inc. P. Nash has received research grants and honoraria for advice and lectures from AbbVie, Lilly, Novartis, Pfizer Inc., Sanofi, Roche, and UCB. C.A. Zerbini has received research grants from, and is on the speakers' bureau for, Pfizer Inc. R. Fleischmann has received research grants and consulting fees from Pfizer Inc.; C. Charles-Schoeman, MD, MS, Associate Professor of Medicine, UCLA; D. van der Heijde, MD, PhD, Professor of Rheumatology, Leiden University Medical Center; G.R. Burmester, MD, Professor of Medicine and Director, Department of Rheumatology and Clinical Immunology, Charité-University Medicine Berlin Free University and Humboldt University of Berlin; P. Nash, MBBS, FRACP, Director, Rheumatology Research Unit, Nambour Hospital, and Associate Professor, Department of Medicine, University of Queensland; C.A. Zerbini, MD, Director, Centro Paulista de Investigação Clinica; C.A. Connell, PhD, Senior Director of Clinical Research, Pfizer Inc., Groton; H. Fan, MS, Statistician/Director, Pfizer Inc., Collegeville; K. Kwok, MS, Director of Biostatistics, Pfizer Inc., New York; E. Bananis, PhD, Medical Director, Pfizer Inc., New York; R. Fleischmann, MD, Co-medical Director, Metroplex Clinical Research Center, and Clinical Professor, Department of Internal Medicine, University of Texas Southwestern Medical Center.

المصدر: The Journal of rheumatology [J Rheumatol] 2018 Feb; Vol. 45 (2), pp. 177-187. Date of Electronic Publication: 2017 Nov 15.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Journal Of Rheumatology Publishing Co Country of Publication: Canada NLM ID: 7501984 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 0315-162X (Print) Linking ISSN: 0315162X NLM ISO Abbreviation: J Rheumatol Subsets: MEDLINE

مواضيع طبية MeSH: Antirheumatic Agents/*therapeutic use , Arthritis, Rheumatoid/*drug therapy , Glucocorticoids/*therapeutic use , Methotrexate/*therapeutic use , Piperidines/*therapeutic use , Protein Kinase Inhibitors/*therapeutic use , Pyrimidines/*therapeutic use , Pyrroles/*therapeutic use, Adult ; Aged ; Disability Evaluation ; Disease Progression ; Double-Blind Method ; Drug Synergism ; Drug Therapy, Combination ; Female ; Follow-Up Studies ; Glucocorticoids/administration & dosage ; Health Surveys ; Humans ; Male ; Middle Aged ; Piperidines/administration & dosage ; Protein Kinase Inhibitors/administration & dosage ; Pyrimidines/administration & dosage ; Pyrroles/administration & dosage ; Treatment Outcome

المؤلفون: Weinblatt ME; Brigham and Women's Hospital, Boston, Massachusetts., Bingham CO 3rd; Johns Hopkins University, Baltimore, Maryland., Burmester GR; Charité University Medicine Berlin, Berlin, Germany., Bykerk VP; Weill Cornell Medical College, New York, New York., Furst DE; University of California, Los Angeles., Mariette X; Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, INSERM U1184, Le Kremlin Bicêtre, France., van der Heijde D; Leiden University Medical Center, Leiden, The Netherlands., van Vollenhoven R; Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands., VanLunen B; UCB Pharma, Raleigh, North Carolina., Ecoffet C; UCB Pharma, Brussels, Belgium., Cioffi C; UCB Pharma, Raleigh, North Carolina., Emery P; University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK.

المصدر: Arthritis & rheumatology (Hoboken, N.J.) [Arthritis Rheumatol] 2017 Oct; Vol. 69 (10), pp. 1937-1948. Date of Electronic Publication: 2017 Sep 12.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 101623795 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2326-5205 (Electronic) Linking ISSN: 23265191 NLM ISO Abbreviation: Arthritis Rheumatol Subsets: MEDLINE

مواضيع طبية MeSH: Deprescriptions*, Antirheumatic Agents/*administration & dosage , Arthritis, Rheumatoid/*drug therapy , Certolizumab Pegol/*administration & dosage , Methotrexate/*therapeutic use, Adult ; Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/immunology ; Arthritis, Rheumatoid/physiopathology ; Blood Sedimentation ; Certolizumab Pegol/therapeutic use ; Double-Blind Method ; Drug Therapy, Combination ; Female ; Humans ; Maintenance Chemotherapy ; Male ; Middle Aged ; Remission Induction

المؤلفون: Atsumi T; Hokkaido University Graduate School of Medicine, Sapporo, Japan., Tanaka Y; The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan., Yamamoto K; Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Takeuchi T; Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan., Yamanaka H; Tokyo Women's Medical University, Tokyo, Japan., Ishiguro N; Nagoya University Graduate School and Faculty of Medicine, Nagoya, Japan., Eguchi K; Rheumatic and Collagen Disease Center, Sasebo Chuo Hospital, Sasebo, Nagasaki, Japan., Watanabe A; Tohoku University, Sendai, Japan., Origasa H; Division of Biostatistics and Clinical Epidemiology, The University of Toyama Graduate School of Medicine, Toyama, Japan., Yasuda S; Hokkaido University Graduate School of Medicine, Sapporo, Japan., Yamanishi Y; Hiroshima Rheumatology Clinic, Hiroshima, Japan., Kita Y; Yokohama Rosai Hospital, Yokohama, Japan., Matsubara T; Matsubara Mayflower Hospital, Kato, Japan., Iwamoto M; Division of Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi, Japan., Shoji T; UCB Pharma, Tokyo, Japan., Togo O; UCB Pharma, Tokyo, Japan., Okada T; Astellas Pharma Inc., Tokyo, Japan., van der Heijde D; Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands., Miyasaka N; Department of Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan., Koike T; Hokkaido University Graduate School of Medicine, Sapporo, Japan.; Sapporo Medical Center NTT EC, Sapporo, Hokkaido, Japan.

المصدر: Annals of the rheumatic diseases [Ann Rheum Dis] 2017 Aug; Vol. 76 (8), pp. 1348-1356. Date of Electronic Publication: 2017 Feb 02.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial

بيانات الدورية: Publisher: BMJ Country of Publication: England NLM ID: 0372355 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-2060 (Electronic) Linking ISSN: 00034967 NLM ISO Abbreviation: Ann Rheum Dis Subsets: MEDLINE

مواضيع طبية MeSH: Antirheumatic Agents/*therapeutic use , Arthritis, Rheumatoid/*drug therapy , Certolizumab Pegol/*therapeutic use , Methotrexate/*therapeutic use, Adult ; Deprescriptions ; Disease Progression ; Double-Blind Method ; Drug Therapy, Combination ; Early Medical Intervention ; Female ; Humans ; Male ; Middle Aged ; Prognosis ; Remission Induction ; Retreatment ; Treatment Outcome